Nov 04, 2021

WHO approves Covaxin for emergency use

The World Health Organization (WHO) has granted approval for emergency use to India's government-backed Covid-19 vaccine, Covaxin.

The vaccine was approved in India in January while the third phase of clinical trials was still under way, sparking some concern and criticism.

Bharat Biotech, which makes the vaccine, has since published data suggesting 78% efficacy.

The WHO said in a tweet it believed the benefits far outweighed the risks.

Some experts had pointed to a fast-track approval and incomplete data, but the firm's chairman, Dr Krishna Ella, said the vaccine was "200% safe".

The WHO's expert panel, which authorises emergency approvals, had asked for more data last month while examining the application Bharat Biotech had filed in July.

In its approval it said :

The vaccine was recommended for use in two doses, with a dose interval of four weeks, in all age groups 18 and aboveCovaxin had 78% efficacy against Covid 19 of any severity, 14 or more days after the second dose, and is extremely suitable for low- and middle-income countries due to easy storage requirementsAvailable data on vaccination of pregnant women with the vaccine are insufficient to assess vaccine safety or efficacy in pregnancy

(BBC News)

Top